BeyondSpring Inc.BYSI
Oncology11 cited findings · profile updated 2026-08-20
0.72 USDnot live — refreshed daily
About BeyondSpring Inc.
BeyondSpring Inc. (BYSI) is an oncology research site. The company is investigating Plinabulin in combination with Docetaxel and Pembrolizumab. A Phase 2 03 Study of Plinabulin/docetaxel and pembrolizumab enrolled 47 patients, demonstrating a 12-month overall survival rate of 78.1% and a 24-month overall survival rate of 58.0%. The median progression-free survival in this study was 7.0 months, with a median duration of response of 9.3 months. The disease control rate was 79.5%, and the confirmed objective response rate was 18.2%. The median overall survival was not reached, and the median follow-up was 28.8 months. Additionally, the DUBLIN-4 study enrolled 442 patients.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| 24-month OS rate | 58 % | BeyondSpring Inc. — SEC 8-K (2026-08-14), p.1 |
| Median progression-free survival | 7.0 months | BeyondSpring Inc. — SEC 8-K (2026-08-14), p.2 |
| Median duration of response | 9.3 months | BeyondSpring Inc. — SEC 8-K (2026-08-14), p.2 |
| Disease control rate | 79.5 % | BeyondSpring Inc. — SEC 8-K (2026-08-14), p.2 |
| Confirmed objective response rate | 18.2 % | BeyondSpring Inc. — SEC 8-K (2026-08-14), p.2 |
| 12-month overall survival rate | 78.1 % | BeyondSpring Inc. — SEC 8-K (2026-08-14), p.2 |
Key projects
- Plinabulin/Docetaxel and Pembrolizumab
The Plinabulin/docetaxel and pembrolizumab Phase 2 03 Study enrolled 47 patients and demonstrated a 24-month overall survival rate of 58.0%.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Oncology research library →